A cell permeable bimane-constrained PCNA-interacting peptide

Aimee J Horsfall1,2,3, Beth A Vandborg1,4, Zoya Kikhtyak5

  • 1Institute of Photonics and Advanced Sensing (IPAS), The University of Adelaide Adelaide South Australia 5005 Australia john.bruning@adelaide.edu.au andrew.abell@adelaide.edu.au.

RSC Chemical Biology
|October 27, 2021
PubMed

Insights

Researchers developed a novel, cell-permeable peptidomimetic that targets proliferating cell nuclear antigen (PCNA). This molecule shows high affinity for PCNA, offering a promising avenue for developing new cancer therapies.

Area of Science:

  • Biochemistry
  • Medicinal Chemistry
  • Molecular Biology

Background:

  • Proliferating cell nuclear antigen (PCNA) is crucial for DNA replication and repair, making it a key therapeutic target for cancers.
  • Peptides from human p21 protein bind PCNA with high affinity, inhibiting DNA replication via a 310-helical conformation.

Purpose of the Study:

  • To design and synthesize conformationally constrained peptidomimetics targeting PCNA.
  • To evaluate the binding affinity, structural basis, and cellular activity of these novel PCNA inhibitors.

Main Methods:

  • Synthesis of macrocyclic peptides with covalent linkers between cysteine residues.
  • Binding affinity assessment using KD values.
  • Structural analysis via X-ray crystallography and computational modeling.
  • Cell permeability and localization studies using confocal microscopy.

Main Results:

  • Macrocyclic peptides bound PCNA with KD values from 570 nM to 3.86 μM.
  • The bimane-constrained peptide 7 exhibited the highest affinity and adopted the critical 310-helical conformation.
  • Peptide 7 demonstrated cell permeability and localized to the cytosol of breast cancer cells.
  • The bimane linker provided inherent fluorescence for direct imaging.

Conclusions:

  • Conformational constraint, particularly the 310-helical structure, is vital for high-affinity PCNA binding.
  • Peptide 7 represents a potent, cell-permeable peptidomimetic inhibitor of PCNA.
  • This study advances the development of therapeutic PCNA inhibitors for proliferative diseases.

Related Concept Videos